Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study-Reference-Cited by-同舟云学术

Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study

Published:2010-01-04 Issue:4 Volume:54 Page:538-545
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr. Blood Cancer

Author:

Wagner Lars M.,Perentesis John P.,Reid Joel M.,Ames Matthew M.,Safgren Stephanie L.,Nelson Marvin D.,Ingle Ashish M.,Blaney Susan M.,Adamson Peter C.

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.22407/fullpdf

Reference30 articles.

1. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma;Bisogno;Cancer,2006

2. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group;Pappo;J Clin Oncol,2007

3. Phase II trial of irinotecan in children with refractory solid tumors: A Children's Oncology Group Study;Bomgaars;J Clin Oncol,2007

4. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children;Furman;J Clin Oncol,1999

5. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts;Thompson;Clin Cancer Res,1999

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615);European Journal of Cancer;2024-09

2. Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor Board;Cancer;2024-08-25

3. Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database;Frontiers in Pharmacology;2024-08-23

4. The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution;eClinicalMedicine;2024-03

5. Absolute neutrophil count clinical trial eligibility criteria for pediatric oncology phase I and phase I/II trials by sponsorship;Pediatric Blood & Cancer;2024-02-26